On Friday, Following U.S. Stocks were among the “Top Gainers”: BioMarin Pharmaceutical Inc (NASDAQ:BMRN), Cempra Inc (NASDAQ:CEMP)
BioMarin Pharmaceutical Inc (NASDAQ:BMRN), with shares climbed 6.86%, and closed at $123.52, hitting new 52-week high of $124.16.
Cempra Inc (NASDAQ:CEMP), surged 6.70%, and closed at $38.71, hitting new 52-week high of $39.30.
Latest NEWS regarding these Stocks are depicted underneath:
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Formerly on February 25, BioMarin Pharmaceutical Inc. (BMRN), declared financial results for the fourth quarter and full year 2014, counting full year proceeds of $751.0 million, a 37% raise over 2013. For the quarter ended December 31, 2014, Non-GAAP net loss declined to $11.4 million ($0.08 per share, basic and diluted) for the fourth quarter of 2014, contrast to non-GAAP net loss of $15.8 million ($0.11 per share, basic and diluted) for the fourth quarter of 2013. For the year ended December 31, 2014, non-GAAP net loss was reduced to $25.9 million ($0.18 per share, basic and diluted), contrast to non-GAAP net loss of $40.4 million ($0.29 per share, basic and $0.30 per share diluted) for the year ended December 31, 2013.
GAAP net loss was $69.8 million ($0.47 per share, basic and diluted) for the fourth quarter of 2014, contrast to GAAP net loss of $62.0 million ($0.43 per share basic and $0.44 per share diluted) for the fourth quarter of 2013. GAAP net loss for the year ended December 31, 2014 was $134.0 million ($0.92 per share, basic and diluted), contrast to GAAP net loss of $176.4 million ($1.28 per share, basic and diluted) for the year ended December 31, 2013. As of December 31, 2014, BioMarin had cash, cash equivalents and investments totaling $1,043.1 million, as contrast to $1,114.7 million on September 30, 2014.
“BioMarin delivered another year of strong results from our five commercialized products. Our accomplishments in 2014 have set the stage for a very productive 2015 both in terms of commercial success and clinical and regulatory milestones,” said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. “The attainment of Prosensa in January 2015 adds exciting potential products to our rare disease portfolio. Importantly for shareholders, we believe the near-term approval of drisapersen in either the U.S. or Europe will drive us to profitability on a non-GAAP basis in 2017. Of even greater significance, we can now leverage our capabilities getting orphan-drugs approved for the benefit of boys with Duchenne Muscular Dystrophy, who presently have no approved treatment options.”
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The corporation’s product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates. Approved products comprise Vimizim(R) (elosulfase alfa) for MPS IVA, a product wholly developed and commercialized by BioMarin; Naglazyme(R) (galsulfase) for MPS VI, a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for MPS I, a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany and Firdapse(R) (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS).
Cempra, Inc. (NASDAQ:CEMP)
Formerly on February 25, Cempra, Inc. (CEMP), stated financial results for the quarter and year ended December 31, 2014 and offered an update on recent corporate developments.
Cempra, Inc., a clinical-stage pharmaceutical corporation, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
